Last updated: February 20, 2026
Fluorodopa F-18, a radiotracer used predominantly in positron emission tomography (PET) imaging for Parkinson’s disease and other neurodegenerative disorders, is supplied primarily by specialized cyclotrons and radiopharmacies globally.
Key Manufacturers and Suppliers
| Company Name |
Location |
Capabilities |
Notable Points |
| GE Healthcare |
United States, Europe |
Produces FDOPA via its cyclotron and radiochemistry facilities |
Supplies globally through its radiopharmacy network. |
| Siemens Healthineers |
Germany, US |
Offers FDOPA in select markets, active in radiopharmacy services |
Operates centralized radiopharmacies, collaborates with third-party providers. |
| IBA Molecular |
Belgium, US |
Supplies FDOPA for clinical and research use |
Provides FDOPA in the US through acquisition of POSITRON's assets. |
| Cardinal Health |
United States |
Radiopharmacy solutions, including FDOPA |
Offers FDOPA through U.S. radiopharmacies. |
| Nordion (Canada) |
Canada |
Supplies isotopes, including FDOPA, to North America |
Focuses on research and clinical applications of radiopharmaceuticals. |
| Advanced Technologies & Regenerative Medicine (ATaRM) |
US |
Produces FDOPA in-house at partner sites |
Operates in niche markets, often in academic or research collaborations. |
| Local Radiopharmacies |
Global (varies) |
Custom production based on local cyclotron capacity |
Supply chain dependent on regional infrastructure and demand. |
Production Process and Supply Chain
FDOPA F-18 synthesis requires a cyclotron capable of producing F-18 through proton bombardment of enriched water. The radiotracer then undergoes complex radiochemistry to attach the fluorine-18 isotope to the L-DOPA molecule. Its half-life (approximately 110 minutes) constrains distribution to within a radius typically less than 4 hours from production.
Manufacturers often operate in centralized locations with dedicated cyclotron and radiochemistry units. After synthesis, FDOPA is packaged in radiochromic vials or kits and shipped under strict regulatory controls.
Market Dynamics and Distribution
- Supply Constraints: Limited cyclotron availability restricts the number of production sites.
- Regional Variations: North America, Europe, and Japan have established supply chains. Emerging markets depend on importing FDOPA from licensed providers.
- Regulatory Compliance: Suppliers must obtain FDA, EMA, or Japanese PMDA approvals, aligning with Good Manufacturing Practices (GMP).
Regulatory and Licensing Status
- FDA: Approved FDOPA products are available through licensed radiopharmacies in the US.
- EMA: Similar approval processes exist for European markets, with some suppliers operating under centralized marketing authorization.
- Country-specific: Licensing and production licenses vary, often requiring validation of radiochemistry processes and radiation safety standards.
Competitive Trends and Innovations
- New Production Methods: Research aims to develop generator-based FDOPA or alternative synthetic routes to improve availability.
- Supply Chain Optimization: Remote production with mobile cyclotrons or on-site synthesis at major medical centers improves access.
- Alternative Radiotracers: Competing tracers, like F-18 labeled compounds targeting different pathways, challenge FDOPA's market position.
Summary
FDOPA F-18 supply chains are tightly linked to cyclotron infrastructure. Major suppliers include GE Healthcare, Siemens, IBA Molecular, and Cardinal Health, with regional radiopharmacies supplementing global manufacturing. Distribution relies on proximity to cyclotron facilities due to F-18’s short half-life. Market growth depends on expanding cyclotron capacity, regulatory approval, and regional healthcare investments.
Key Takeaways
- FDOPA F-18 production hinges on cyclotron availability and radiochemistry expertise.
- Supply is concentrated in Europe, North America, and Japan.
- Regulatory approvals are required for commercial distribution in key markets.
- Logistic efficiencies and innovations are critical to enhancing global access.
- Competition arises from new synthetic methods and alternative radiotracers.
FAQs
1. How is FDOPA F-18 produced?
FDOPA F-18 is produced by cyclotron irradiation of enriched water to generate F-18, followed by complex radiochemical synthesis to attach F-18 to L-DOPA. The process requires specialized equipment and facilities.
2. What are the primary challenges in FDOPA supply?
Limited cyclotron capacity, short half-life of F-18, regulatory restrictions, and logistic constraints impede widespread supply.
3. Which countries are leading in FDOPA manufacturing?
The US, Germany, Belgium, and Canada lead in production due to established cyclotron and radiochemistry infrastructure.
4. Are there regional differences in FDOPA availability?
Yes, North American and European markets enjoy better access; other regions often rely on imports.
5. What future developments could impact the FDOPA supply chain?
Emergence of generator-based production methods, regional mobile cyclotrons, and alternative tracers can influence supply dynamics.
References
[1] IAEA. (2022). Production and Quality Assurance of Radiopharmaceuticals. International Atomic Energy Agency.
[2] NEMA. (2020). Guidelines for Radiopharmaceutical Manufacturing. Image of radiopharmaceutical production standards.
[3] FDA. (2022). Approved Radioactive Drug Products Containing Fluorodopa F-18. Food and Drug Administration.
[4] EMA. (2021). Market Authorization for Radiopharmaceuticals. European Medicines Agency.
